Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.56 |
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | PKM | P14618 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 9/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8331402 | 0.84 | ALDH1A1 (0.43) | RAB9AMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL23290946 | 0.84 | ALDH1A1 (0.43) | RAB9AMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL12210694 | 0.81 | NSD1 (0.39) | RAB9AMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL19783572 | 0.78 | RAB9A (0.62) | RAB9AMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL2615996 | 0.76 | RAB9A (0.56) | RAB9AMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL474219 | 0.76 | ALDH1A1 (0.61) | RAB9AMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL335937 | 0.76 | ALDH1A1 (0.61) | RAB9AMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL20554157 | 0.75 | NR1H4 (0.39) | LMNAGAA | |
| SCHEMBL2634141 | 0.72 | SMN1; SMN2 (0.61) | RAB9AMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13439534 | 0.72 | RAB9A (0.51) | RAB9AMAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117120423-B | Indolylamine 2, 3-dioxygenase inhibitors, methods of preparing the same, and pharmaceutical compositions containing the same | 柳韩洋行 | 2026-02-27 | — | — | CN | disclosed |
| EP-4015510-B1 | ANTI-TUMOUR COMPOUND BASED ON JWA GENE ACTIVATION AND HER2 DEGRADATION, PREPARATION METHOD THEREFOR, AND USE THEREOF | Simcere pharmaceutical co ltd (CN) | 2025-08-20 | — | — | EP | disclosed |
| US-20250011293-A1 | LEUKOTRIENE SYNTHESIS INHIBITORS | NAEGIS PHARMACEUTICALS INC. (CA) | 2025-01-09 | — | — | US | disclosed |
| US-20240174636-A1 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-05-30 | — | — | US | disclosed |
| US-11976052-B2 | Leukotriene synthesis inhibitors | NAEGIS PHARMACEUTICALS INC. (CA) | 2024-05-07 | — | — | US | disclosed |
| EP-4313965-A1 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Yuhan Corporation (KR) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120423-A | Novel indoleamine 2,3-dioxygenase inhibitors, process for preparing the same and pharmaceutical compositions containing the same | 柳韩洋行 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022203332-A1 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2022-09-29 | — | — | WO | disclosed |
| US-11427575-B2 | Antitumor compound for activating JWA gene and degrading HER2, preparation method thereof, and application thereof | SIMCERE PHARMACEUTICAL CO., LTD. (CN) | 2022-08-30 | — | — | US | disclosed |
| EP-4015510-A1 | ANTI-TUMOUR COMPOUND BASED ON JWA GENE ACTIVATION AND HER2 DEGRADATION, PREPARATION METHOD THEREFOR, AND USE THEREOF | Simcere Pharmaceutical Co. Ltd. (CN) | 2022-06-22 | — | — | EP | disclosed |
| WO-2004100881-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
| EP-1087962-A4 | PREPARATION OF HETEROARYL COMPOUNDS | LILLY CO ELI (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-1087962-A1 | PREPARATION OF HETEROARYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065896-A1 | PREPARATION OF HETEROARYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
| EP-0060426-B1 | N-(2,2,2-TRIFLUOROETHYL)-N-ALKYL-AZOLYLOXYACETIC-ACID AMIDES, THEIR PREPARATION AND USE AS HERBICIDES AND INTERMEDIATES FOR THEIR PREPARATION | BAYER AG (DE) | 1986-04-23 | — | — | EP | disclosed |
| US-4465504-A | Herbicidally active novel N-(2,2,2-trifluoroethyl)-N-alkyl-azolyloxyacetic acid amides and intermediates therefor | BAYER AKTIENGESELLSCHAFT (DE) | 1984-08-14 | — | — | US | disclosed |
| US-4455428-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1984-06-19 | — | — | US | disclosed |
| US-4408055-A | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1983-10-04 | — | — | US | disclosed |
| EP-0081730-A1 | Process for the preparation of hetaryloxyacetamides | BAYER AG (DE) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174636-A1 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | IDO1, IDO2, INMT | RAB9A 2470/4885MAPT 2422/4885MEN1 3028/4885 |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | RAB9A 2066/4885MAPT 4379/4885MEN1 4348/4885 |
| US-11427575-B2 | Antitumor compound for activating JWA gene and degrading HER2, preparation method thereof, and application thereof | EGFR, ERBB2, ERBB3 | RAB9A 1648/4885MAPT 4856/4885MEN1 2781/4885 |
| US-11976052-B2 | Leukotriene synthesis inhibitors | LTC4S, LTB4R2, LTA4H | RAB9A 4666/4885MAPT 3739/4885MEN1 3388/4885 |
| US-20250011293-A1 | LEUKOTRIENE SYNTHESIS INHIBITORS | LTC4S, LTB4R2, LTA4H | RAB9A 4666/4885MAPT 3739/4885MEN1 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.